Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2019 Dec;71(12):1583–1592. doi: 10.1002/acr.23820

Figure 1.

Figure 1.

Flow diagram of study sample. CCP= cyclic citrullinated peptide antibody; RA= rheumatoid arthritis; SRD= systemic rheumatic disease; ACR/EULAR= American College of Rheumatology and European League Against Rheumatism. *Other SRD= systemic lupus erythematosus, scleroderma, dermatomyositis, polymyositis, seronegative spondyloarthropathies (including ankylosing spondylitis, reactive arthritis, psoriatic arthritis), antiphospholipid syndrome, mixed connective tissue disease, Sjögren’s syndrome, systemic vasculitis (including Takayasu arteritis, giant cell arteritis, polyarteritis nodosa, Behçet’s disease, Henoch-Schönlein purpura, ANCA-associated vasculitis), polymyalgia rheumatica, dermatomyositis, and juvenile idiopathic arthritis.